BONITA SPRINGS, Fla., Jan. 31 /PRNewswire/ -- Tigris Pharmaceuticals, Inc., a privately held drug development company, is pleased to announce the appointment of Mr. Pedro Granadillo to its Board of Directors.
Mr. Granadillo served as Senior Vice President for Eli Lilly and Company (“Lilly”) until 2004 when he retired after 34 years of service. He was member of Lilly’s Policy Committee, which was comprised of its top seven executives. As Lilly’s top human resources, manufacturing and quality executive, he was responsible for policies affecting a global workforce of more than 45,000 employees, as well as, a broad network of manufacturing facilities for its extensive line of products. Mr. Granadillo led initiatives that brought Lilly wide recognition as a progressive employer. He also oversaw more than 20 sites and 13,000 employees involved in the manufacturing of Lilly’s conventional “small-molecule” pharmaceuticals and “large-molecule” biotech therapies.
“Pedro’s appointment brings to the Board three decades of industry knowledge and extensive pharmaceutical development and management experience,” said Edmundo Muniz, Chief Executive Officer of Tigris. “His past experience and proven track record in corporate management, human resources, manufacturing and quality assurance will be instrumental as we drive our clinical and preclinical programs forward.”
“I am excited to be joining Tigris at this important time in the Company’s development,” said Mr. Granadillo. “I look forward to working with the management team, the Board and the Company’s investors in implementing the Company’s strategic business plans over the next year and beyond.”
Mr. Granadillo is currently a member of the boards of directors of Haemonetics Corporation of Braintree, MA; Noven Pharmaceuticals, Miami, FL; and Nile Therapeutics, San Francisco, CA. Mr. Granadillo earned his B.S. degree in Industrial Engineering from Purdue University.
About Tigris Pharmaceuticals, Inc.
Tigris Pharmaceuticals, Inc. is a privately held biopharmaceutical company that develops therapeutic technologies to treat oncology, infectious diseases and other areas of unmet medical need. Tigris is currently conducting a Phase II clinical study for A-007, its topical treatment for pre-cancerous and cancerous anogenital lesions associated with HPV. Tigris is also developing three novel, targeted small molecule oncology compounds. Tigris’ mission is to efficiently move its existing and future technologies through the various stages of clinical development in order to meet patients’ needs for safe and effective treatments of human illnesses.
info@tigrispharma.com
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other governmental regulation, our pharmaceutical collaborator’s ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third party reimbursement, and other factors described in our filings with the Securities and Exchange Commission.
CONTACT: Anne White, Chief Operating Officer of Tigris Pharmaceuticals,
Inc., +1-239-444-5400, info@tigrispharma.com
